{
    "Trade/Device Name(s)": [
        "Wondfo One Step Buprenorphine Urine Test Strip",
        "Wondfo One Step Oxycodone Urine Test Strip",
        "Wondfo One Step Propoxyphene Urine Test Strip"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K093175",
    "Predicate Device Reference 510(k) Number(s)": [
        "K060466",
        "K033047",
        "K040445"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG",
        "JXN"
    ],
    "Summary Letter Date": "August 25, 2010",
    "Summary Letter Received Date": "August 24, 2010",
    "Submission Date": "August 20, 2010",
    "Regulation Number(s)": [
        "21CFR862.3650",
        "21CFR862.3700"
    ],
    "Regulation Name(s)": [
        "Opiate Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Buprenorphine",
        "Oxycodone",
        "Propoxyphene"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow",
        "Competitive binding"
    ],
    "Methodologies": [
        "Immunoassay",
        "Lateral flow immunochromatographic"
    ],
    "Submission Type(s)": [
        "Strip test"
    ],
    "Document Summary": "FDA 510(k) summary for Wondfo One Step Buprenorphine, Oxycodone, and Propoxyphene Urine Test Strips for qualitative detection of drugs of abuse in human urine using immunochromatographic lateral flow technology.",
    "Indications for Use Summary": "Qualitative determination of buprenorphine (10 ng/mL), oxycodone (100 ng/mL), and propoxyphene (300 ng/mL) in human urine at specified cut-off concentrations, for laboratory professional use only (not for point-of-care), for in vitro diagnostic use.",
    "fda_folder": "Toxicology"
}